Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine

Archives of Gynecology and Obstetrics

Volumn 285, Issue 6, 2012, Pages 1719-1724

  Sotiriadis, Alexandros ^a   Dagklis, Themistoklis ^a   Siamanta, Vaia ^a   Chatzigeorgiou, Konstantinos ^a   Agorastos, Theodoros ^a  

^a Ippokration Hospital Thessaloniki   (Greece)

Author keywords

Acceptability; HPV; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ADVERSE DRUG REACTION; ARTICLE; FEAR; FEMALE; HEALTH BEHAVIOR; HUMAN; KNOWLEDGE; MEDICAL INFORMATION; RESIDENTIAL AREA; RURAL AREA; SOCIOECONOMICS; VACCINATION;

ADULT; FEAR; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84864495463     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-011-2208-z     Document Type: Article

References (40)

1. Quinn M, Babb P, Jones J, Allen E (1999) Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318: 904-908
2. Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC (1985) Evaluation of screening programmes for gynaecological cancer. Br J Cancer 52:669-673
3. Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M et al (2011) Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675-2686
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19
5. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459-1466
6. Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861-1868
7. Watson M, Shaw D, Molchanoff L, McInnes C (2009) Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 33:365-370
8. Berry-Caban CS, Buenaventura JB (2009) HPV vaccination coverage among adolescents aged 9 to 17 years in a United States military treatment facility. Int J Adolesc Med Health 21:567-570
9. Rouzier R, Giordanella JP (2010) Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J Adolesc Health 47:237-241
10. Dempsey AF, Zimet GD, Davis RL, Koutsky L (2006) Factors that are associated with parental acceptance of human papillo-mavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 117:1486-1493
11. Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D et al (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 373:1949-1957
12. Jain N, Euler GL, Shefer A, Lu P, Yankey D et al (2009) Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med 48:426-431
13. Chao C, Velicer C, Slezak JM, Jacobsen SJ (2010) Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol 171:357-367
14. Pruitt SL, Schootman M (2010) Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med 38:525-533
15. Kwon Y, Cho HY, Lee YK, Bae GR, Lee SG (2010) Relationship between intention of novel influenza A (H1N1) vaccination and vaccination coverage rate. Vaccine 29:161-165
16. (No authors listed) (2010) Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage-United States, October 2009-January 2010. MMWR Morb Mortal Wkly Rep 59:363-368
17. Constantine NA, Jerman P (2007) Acceptance of human papil-lomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 40:108-115
18. (No authors listed) (2009) Intent to receive influenza A (H1N1) 2009 monovalent and seasonal influenza vaccines-two counties, North Carolina, August 2009. MMWR Morb Mortal Wkly Rep 58:1401-1405
19. Eastwood K, Durrheim DN, Jones A, Butler M (2010) Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med J Aust 192:33-36
20. Hoover DR, Carfioli B, Moench EA (2000) Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 21:375-391
21. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL (2003) Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 30:774-778
22. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI (2003) Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 14:300-306
23. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM et al (2006) Are women ready for the HPV vaccine? Gynecol Oncol 103:151-154
24. Cook RL, Zhang J, Mullins J, Kauf T, Brumback B et al (2010) Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health 47:596-599
25. Cui Y, Baldwin SB, Wiley DJ, Fielding JE (2010) Human pap-illomavirus vaccine among adult women: disparities in awareness and acceptance. Am J Prev Med 39:559-563
26. Gamble HL, Klosky JL, Parra GR, Randolph ME (2010) Factors influencing familial decision-making regarding human papillo-mavirus vaccination. J Pediatr Psychol 35:704-715
27. Kang HS, Moneyham L (2011) Attitudes, intentions, and perceived barriers to human papillomavirus vaccination among Korean high school girls and their mothers. Cancer Nurs 34: 202-208
28. Sundstrom K, Tran TN, Lundholm C, Young C, Sparen P et al (2010) Acceptability of HPV vaccination among young adults aged 18-30 years-a population based survey in Sweden. Vaccine 28:7492-7500
29. Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD (2010) Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. BMC Womens Health 10:27
30. Dempsey A, Cohn L, Dalton V, Ruffin M (2011) Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine 29:528-534
31. Lower J (2008) Two unclear cases of death. Can we still recommend HPV vaccination? MMW Fortschr Med 150:6
32. Coombes R (2009) Cervarix: definitely not the new MMR. BMJ 339:b4124
33. Bakogianni GD, Nikolakopoulos KM, Nikolakopoulou NM (2010) HPV vaccine acceptance among female Greek students. Int J Adolesc Med Health 22:271-273
34. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM (2009) Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 27:7270-7281
35. Pomfret TC, Gagnon JM Jr, Gilchrist AT (2011) Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 36:1-9
36. Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI et al (2009) Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt) 18:1679-1686
37. Bernard DM, Cooper Robbins SC, McCaffery KJ, Scott CM, Skinner SR (2011) The domino effect: adolescent girls' response to human papillomavirus vaccination. Med J Aust 194:297-300
38. Hilton S, Hunt K, Langan M, Bedford H, Petticrew M (2010) Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005-2008). Soc Sci Med 70:942-950
39. Habel MA, Liddon N, Stryker JE (2009) The HPV vaccine: a content analysis of online news stories. J Womens Health (Larchmt) 18:401-407
40. Keelan J, Pavri V, Balakrishnan R, Wilson K (2010) An analysis of the Human Papilloma Virus vaccine debate on MySpace blogs. Vaccine 28:1535-1540